Antiarrhythmic drug therapy for atrial fibrillation

Circulation

Volumn 125, Issue 2, 2012, Pages 381-389

  Zimetbaum, Peter ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

antiarrhythmic agents; antiarrhythmic drugs; atrial fibrillation; atrial fibrillation arrhythmia; atrial flutter

Indexed keywords

ALDOSTERONE ANTAGONIST; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; BUDIODARONE; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; FLUOXETINE; HALOPERIDOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUTILIDE; PHENYTOIN; PLACEBO; PRAVASTATIN; PROPAFENONE; QUINIDINE; QUINIDINE GLUCONATE; QUINIDINE SULFATE; RANOLAZINE; SIMVASTATIN; SOTALOL; UNINDEXED DRUG; VERAPAMIL; VERNAKALANT; WARFARIN;

ALOPECIA; ANGINA PECTORIS; ANOREXIA; ANTIARRHYTHMIC ACTIVITY; ANTICHOLINERGIC EFFECT; ARTICLE; ATAXIA; BLURRED VISION; BRADYCARDIA; BRONCHOSPASM; BRUGADA SYNDROME; CARDIOVERSION; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG WITHDRAWAL; DYSGEUSIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEPATITIS; HUMAN; HYPERTHYROIDISM; HYPOTENSION; HYPOTHYROIDISM; INOTROPISM; INTERSTITIAL LUNG DISEASE; LIVER TOXICITY; LUNG NODULE; LUNG TOXICITY; METALLIC TASTE; MYOSITIS; NAUSEA; PACEMAKER; PARESTHESIA; PHOTOSENSITIVITY DISORDER; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; RASH; RESPIRATORY DISTRESS SYNDROME; RISK FACTOR; SIDE EFFECT; SINUS BRADYCARDIA; SINUS RHYTHM; SKIN DISCOLORATION; SNEEZING; STROKE; SUPRAVENTRICULAR TACHYCARDIA; TASTE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TINNITUS; TORSADE DES POINTES; TREMOR; URINE RETENTION; VISUAL DISORDER; XEROSTOMIA;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HUMANS; TREATMENT OUTCOME;

EID: 84856088658     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.111.019927     Document Type: Article

References (65)

1. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-1833. (Pubitemid 35417773)
2. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, Tebbe U. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: The Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690-1696. (Pubitemid 36584236)
3. Opolski G, Torbicki A, Kosior DA, Szulc M, Wozakowska-Kaplon B, Kolodziej P, Achremczyk P. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest. 2004;126:476-486. (Pubitemid 39093433)
4. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJ, Tijssen JG, Crijns HJ. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-1840. (Pubitemid 35417774)
5. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation: Pharmacological Intervention in Atrial Fibrillation (PIAF): A randomised trial. Lancet. 2000;356:1789-1794.
6. Zimetbaum P. Is rate control or rhythm control preferable in patients with atrial fibrillation? An argument for maintenance of sinus rhythm in patients with atrial fibrillation. Circulation. 2005;111:3150 -3156; discussion 3156-3157.
7. Martin-Doyle W, Essebag V, Zimetbaum P, Reynolds MR. Trends in us hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials. J Cardiovasc Electrophysiol. 2011;22: 548-553. National prescription audit™ 2006 -2010. (Extracted January 2011)
8. IMF Health. National prescription audit™: 2006 -2010. (Extracted January 2011)
9. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:2369-2429.
10. Sokolow M. Quinidine for the treatment of benign auricular fibrillation with repeated emboli. Am Heart J. 1939:494-499.
11. Belhassen B, Glick A, Viskin S. Efficacy of quinidine in high-risk patients with Brugada syndrome. Circulation. 2004;110:1731-1737. (Pubitemid 39299213)
12. Shimuzu WOT, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura S, Kamiya T, Shimomura K. Effects of verapamil and propranolol on early after depolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol. 1995;26: 1299-1209.
13. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, Casey S, Maron BJ. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45:1251-1258. (Pubitemid 40523146)
14. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, Arensberg D, Baker A, Friedman L, Greene HL; for the CAST investigators. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991;324:781-788.
15. Huang DT, Monahan KM, Zimetbaum P, Papageorgiou P, Epstein LM, Josephson ME. Hybrid pharmacologic and ablative therapy: A novel and effective approach for the management of atrial fibrillation. J Cardiovasc Electrophysiol. 1998;9:462-469.
16. Nabar A, Rodriguez LM, Timmermans C, van Mechelen R, Wellens HJ. Class IC antiarrhythmic drug induced atrial flutter: Electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation. Heart. 2001;85:424-429. (Pubitemid 32973531)
17. Gentzkow GD, Sullivan JY. Extracardiac adverse effects of flecainide. Am J Cardiol. 1984;53:101B-105B. (Pubitemid 14193849)
18. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB Jr. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation. 2000;102:2385-2390.
19. Kober L, Bloch Thomsen PE, Moller M, Torp-Pedersen C, Carlsen J, Sandoe E, Egstrup K, Agner E, Videbaek J, Marchant B, Camm AJ. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: A randomised trial. Lancet. 2000;356: 2052-2058. (Pubitemid 32009820)
20. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, Kober L, Sandoe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ; Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med. 1999;341:857-865. (Pubitemid 29427047)
21. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med. 2007; 356:935-941.
22. Essebag V, Reynolds MR, Hadjis T, Lemery R, Olshansky B, Buxton AE, Josephson ME, Zimetbaum P. Sex differences in the relationship between amiodarone use and the need for permanent pacing in patients with atrial fibrillation. Arch Intern Med. 2007;167:1648-1653. (Pubitemid 47280346)
23. Kaufman ES, Zimmermann PA, Wang T, Dennish GW III, Barrell PD, Chandler ML, Greene HL. Risk of proarrhythmic events in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study: A multivariate analysis. J Am Coll Cardiol. 2004;44:1276-1282. (Pubitemid 39208885)
24. Meng X, Mojaverian P, Doedee M, Lin E, Weinryb I, Chiang ST, Kowey PR. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. Am J Cardiol. 2001;87:432-435. (Pubitemid 32150001)
25. Becquemont L, Neuvonen M, Verstuyft C, Jaillon P, Letierce A, Neuvonen PJ, Funck-Brentano C. Amiodarone interacts with simvastatin but not with pravastatin disposition kinetics. Clin Pharmacol Ther. 2007; 81:679-684. (Pubitemid 46625102)
26. Dusman RE, Stanton MS, Miles WM, Klein LS, Zipes DP, Fineberg NS, Heger JJ. Clinical features of amiodarone-induced pulmonary toxicity. Circulation. 1990;82:51-59. (Pubitemid 20216315)
27. Siniakowicz RM, Narula D, Suster B, Steinberg JS. Diagnosis of amiodarone pulmonary toxicity with high-resolution computerized tomographic scan. J Cardiovasc Electrophysiol. 2001;12:431-436. (Pubitemid 32324657)
28. Cohen-Lehman J, Dahl P, Danzi S, Klein I. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6:34-41.
29. Kober L, Torp-Pedersen C, McMurray JJ, Gotzsche O, Levy S, Crijns H, Amlie J, Carlsen J. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358:2678-2687. (Pubitemid 351860860)
30. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, Aliot EM, Hohnloser SH. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987-999. (Pubitemid 47367078)
31. Hohnloser SH, Crijns HJ, van Eickels M, Gaudin C, Page RL, Torp- Pedersen C, Connolly SJ. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360:668-678.
32. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eickels M, Gaudin C, Page RL, Hohnloser SH. Analysis of stroke in ATHENA: A placebo-controlled, double-blind, parallel-arm trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation. 2009;120:1174-1180.
33. Freemantle N, Lafuente-Lafuente C, Mitchell S, Laurent E, Reynolds M. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Europace. 2011;13:329-345.
34. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum A, Blomstrom P, Borggrefe M, Budaj A, Chen A, Ching CK, Commerford P, Dans A, Davy JM, Delacretaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbuchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimjan C, Paolasso, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsanyi J, Torp- Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268-2276.
35. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: The DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597-605.
36. FDA statement for dronedarone. FDA Web site. http://www.fda.gov/ drugs/drugsafety/ucm240011.html. Accessed December 19, 2011.
37. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, Rasmussen SL, Stiell IG, Coutu B, Ip JH, Pritchett EL, Camm AJ. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation. 2008;117: 1518-1525. (Pubitemid 351440640)
38. Kowey PR, Dorian P, Mitchell LB, Pratt CM, Roy D, Schwartz PJ, Sadowski J, Sobczyk D, Bochenek A, Toft E. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: A randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009;2:652-659.
39. Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011;57:313-321.
40. Arya A, Silberbauer J, Teichman S, Milner P, Sulke N, Camm AJ. A preliminary assessment of the effects of ATI-2042 in subjects with paroxysmal atrial fibrillation using implanted pacemaker technology. Europace. 2009;11:458-464.
41. Scirica BM, Morrow DA, Hod H, Murphy SA, Belardinelli L, Hedgepeth CM, Molhoek P, Verheugt FW, Gersh BJ, McCabe CH, Braunwald E. Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: Results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. Circulation. 2007;116: 1647-1652. (Pubitemid 47537839)
42. Burashnikov A, Sicouri S, Di Diego JM, Belardinelli L, Antzelevitch C. Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol. 2010;56:1216-1224.
43. Sicouri S, Burashnikov A, Belardinelli L, Antzelevitch C. Synergistic electrophysiologic and antiarrhythmic effects of the combination of ranolazine and chronic amiodarone in canine atria. Circ Arrhythm Electrophysiol. 2010; 3:88-95.
44. Wu L, Guo D, Li H, Hackett J, Yan GX, Jiao Z, Antzelevitch C, Shryock JC, Belardinelli L. Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine. Heart Rhythm. 2008;5: 1726-1734.
45. Wu L, Ma J, Li H, Wang C, Grandi E, Zhang P, Luo A, Bers DM, Shryock JC, Belardinelli L. Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization. Circulation. 2011;123:1713-1720.
46. Orth PM, Hesketh JC, Mak CK, Yang Y, Lin S, Beatch GN, Ezrin AM, Fedida D. Rsd1235 blocks late INa and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res. 2006;70:486-496.
47. Kawabata M, Hirao K, Higuchi K, Sasaki T, Furukawa T, Okada H, Hachiya H, Isobe M. Clinical and electrophysiological characteristics of patients having atrial flutter with 1:1 atrioventricular conduction. Europace. 2008;10:284-288. (Pubitemid 351773733)
48. Hudson CJ, Whitner TE, Rinaldi MJ, Littmann L. Brugada electrocardiographic pattern elicited by inadvertent flecainide overdose. Pacing Clin Electrophysiol. 2004;27:1311-1313. (Pubitemid 39281929)
49. Krishnan SC, Josephson ME. ST segment elevation induced by class IC antiarrhythmic agents: Underlying electrophysiologic mechanisms and insights into drug-induced proarrhythmia. J Cardiovasc Electrophysiol. 1998;9:1167-1172. (Pubitemid 28516144)
50. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care. Am Heart J. 1986;111:1088-1093. (Pubitemid 16085013)
51. Kozhevnikov DO, Yamamoto K, Robotis D, Restivo M, El-Sherif N. Electrophysiological mechanism of enhanced susceptibility of hypertrophied heart to acquired torsade de pointes arrhythmias: Tridimensional mapping of activation and recovery patterns. Circulation. 2002;105: 1128-1134. (Pubitemid 34212625)
52. Wann LS, Curtis AB, January CT, Ellenbogen KA, Lowe JE, Estes NA III, Page RL, Ezekowitz MD, Slotwiner DJ, Jackman WM, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Le Heuzey JY, Crijns HJ, Olsson SB, Prystowsky EN, Halperin JL, Tamargo JL, Kay GN, Jacobs AK, Anderson JL, Albert N, Hochman JS, Buller CE, Kushner FG, Creager MA, Ohman EM, Ettinger SM, Guyton RA, Tarkington LG, Yancy CW. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;123: 104-123.
53. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B; Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med. 2000;342:913-920. (Pubitemid 30177051)
54. Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-1872.
55. Fetsch TBP, Engberding R, Koch H, Luki J, Meinertz T, Oeff M, Seipel L, Trappe H, Treese N, Breithardt G. Prevention of atrial fibrillation after cardioversion: Results of the PAFAC trial. Eur Heart J. 2004;25:1385.
56. Stambler BWM, Ellenbogen K; Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation. 1996;7: 1613-1621. (Pubitemid 26320266)
57. Galve E, Rius T, Ballester R, Artaza MA, Arnau JM, Garcia-Dorado D, Soler-Soler J. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol. 1996;27:1079-1082. (Pubitemid 26117695)
58. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, Calzolari M, Solano A, Baroffio R, Gaggioli G. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351:2384-2391. (Pubitemid 40485990)
59. Zimetbaum PJ, Schreckengost VE, Cohen DJ, Lemery R, Love D, Epstein LM, Laham R, Josephson ME. Evaluation of outpatient initiation of antiarrhythmic drug therapy in patients reverting to sinus rhythm after an episode of atrial fibrillation. Am J Cardiol. 1999;83:450-452, A459.
60. Hauser TH, Pinto DS, Josephson ME, Zimetbaum P. Safety and feasibility of a clinical pathway for the outpatient initiation of antiarrhythmic medications in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2003;91:1437-1441. (Pubitemid 36694720)
61. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for the European Society of Cardiology guidelines. Europace. 2011;13:308-328.
62. Schneider MP, Hua TA, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by renin-angiotensin system inhibition: A meta-analysis. J Am Coll Cardiol. 2010;55:2299-2307.
63. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention for End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45:712-719. (Pubitemid 40282586)
64. Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, Lucci D, Di Pasquale G, Tognoni G. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360:1606-1617.
65. Patti G, Chello M, Candura D, Pasceri V, D'Ambrosio A, Covino E, Di Sciascio G. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: Results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study. Circulation. 2006;114:1455-1461. (Pubitemid 44526999)